Innate immune genes synergize to predict increased risk of chronic disease in hepatitis C virus infection.
File Type:
PDFItem Type:
Journal ArticleDate:
2011Access:
openAccessCitation:
Dring MM, Morrison MH, McSharry BP, Guinan KJ, Hagan R, O'Farrelly C, Gardiner CM, Innate immune genes synergize to predict increased risk of chronic disease in hepatitis C virus infection., PNAS, 108, 14, 2011, 5736-41Download Item:
Abstract:
Hepatitis C is a common infection with significant morbidity and mortality, and only a minority of patients successfully clear the infection. Identification of factors that influence disease progression in HCV infection is difficult owing to the lack of well-defined patient cohorts. However, recent evidence supports a role for the innate immune system in virus clearance. In this study, we investigated innate immune genes for their contribution to disease progression in a unique cohort of well-controlled HCV-infected patients. The Irish cohort of HCV patients is uniquely homogenous; patients were infected with a single genotype of HCV from contaminated anti-D Ig. We genotyped 543 infected patients, including 247 patients who spontaneously resolved infection, for natural killer (NK) cell-associated killer cell Ig-like receptors (KIR) genes and the recently reported IL28B (IFNλ3) SNP. The NK cell gene KIR2DS3 was significantly increased in patients with chronic infection [odds ratio (OR) 1.90, 95% confidence interval (CI) 1.25-2.90, P < 0.002]. The IL28B "T" allele was also significantly increased in chronically infected patients (OR 7.38, 95% CI 4.93-11.07, P < 10(-8)). The presence of both markers synergized to significantly increase the risk of chronic infection over either factor alone (OR 20.11, 95% CI 9.05-44.68, P < 10(-7)). In functional experiments, we found that IL28A significantly inhibited IFN-γ production by NK cells. Thus, we demonstrate a functional link between NK cells and type 3 IFN. Our findings may contribute to the development of a prognostic test for HCV and identify therapeutic strategies for the clinical management of HCV-infected patients.
Sponsor
Grant Number
Science Foundation Ireland (SFI)
Health Research Board (HRB)
Author's Homepage:
http://people.tcd.ie/ofarreclhttp://people.tcd.ie/gardinec
http://people.tcd.ie/smckiern
Description:
PUBLISHEDType of material:
Journal ArticleCollections
Series/Report no:
PNAS108
14
Availability:
Full text availableKeywords:
Hepatitis CSubject (TCD):
Immunology, Inflammation & InfectionDOI:
http://dx.doi.org/10.1073/pnas.1016358108ISSN:
0027-8424Metadata
Show full item recordLicences: